Two new respiratory syncytial virus (RSV) vaccines were recently approved by the FDA: Abrysvo and Beyfortus. But because these vaccines present risks, and since RSV usually only causes mild, cold-like symptoms, the risk versus benefit of using either vaccine is questionable.

See the protocol for preventing and treating RSV developed by the Front Line COVID Critical Care Alliance (FLCCC).

The CDC now recommends Abrysvo, a vaccine for mothers at 32 to 36 weeks of pregnancy, despite a 20% higher rate of premature birth among vaccinated mothers in clinical trials.

The CDC also recommends Beyfortus for infants up to 24 months and newborns entering their first RSV season. Twelve deaths occurred in trials of this vaccine.